Accelerating the clinical development of a novel typhoid-paratyphoid bivalent conjugate vaccine – (VaxPaT)

There is a huge global burden of enteric fever which disrupts the lives of children in settings with inadequate quality water and poor sanitation. Over 60 million doses of typhoid conjugate vaccines have been rolled out in the past 3 years, but there is no licensed vaccine available against Salmonella Paratyphi A (SPA), which remains the cause of one-third of the global burden of enteric fever each year, amounting to about 2-3 million cases. In addition, there is a concern that there could be serovar replacement following typhoid vaccine deployment. A bivalent Salmonella vaccine could provide combined protection against enteric fever whilst minimising the immunisation burden. We propose this study to accelerate the development of a novel typhoid- paratyphoid bivalent conjugate vaccine by testing its efficacy using an established paratyphoid controlled human infection model (CHIM). The applicants are world-leading researchers in the field of enteric fever with a track record in conducting clinical vaccine trials and CHIMs. We will work with industry partners and existing funded collaborations to deliver data expected to be pivotal to support global licensure and deployment of enteric fever vaccines.